(Total Views: 667)
Posted On: 03/31/2022 2:19:55 PM
Post# of 153991
Yup, that is a good summary.
This part makes my Bloody Mary go down better.
Boston institution looking at TmE
NYC looking at Glioblastoma
Checkpoint inhibitors (MD Andy?)
London institution looking at Alzheimer’s
“ Scott Kelly. Have been contacted by academic institutions interested in Leronlimab. One institution in Boston is specifically interested in tumor micro-environment; hospital in NYC is interested in studying brain tumors. There may also be a study on checkpoint inhibitors, and an institution in London is interested in Alzheimer’s. Looking at Leronlimab as long-acting (3 month) HIV prevention agent. Looking at HIV and NASH applications where we don’t have to pay for the trial. Processing 3 articles for peer-reviewed publication.”
This part makes my Bloody Mary go down better.
Boston institution looking at TmE
NYC looking at Glioblastoma
Checkpoint inhibitors (MD Andy?)
London institution looking at Alzheimer’s
“ Scott Kelly. Have been contacted by academic institutions interested in Leronlimab. One institution in Boston is specifically interested in tumor micro-environment; hospital in NYC is interested in studying brain tumors. There may also be a study on checkpoint inhibitors, and an institution in London is interested in Alzheimer’s. Looking at Leronlimab as long-acting (3 month) HIV prevention agent. Looking at HIV and NASH applications where we don’t have to pay for the trial. Processing 3 articles for peer-reviewed publication.”
(2)
(0)
